echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Huahai is soaring! Take 6 heavyweight varieties 21 overrated varieties dominate the screen.

    Huahai is soaring! Take 6 heavyweight varieties 21 overrated varieties dominate the screen.

    • Last Update: 2020-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharmaceutical Network July 24 - Recently, Huahai Pharmaceuticals released a 2020H1 performance forecast, net profit is expected to be 552 million yuan - 620 million yuan, up 65%-85% YoY, preparations and raw materials sales revenue growth as the main factor driving performance.
    so far this year, Huahai Pharmaceuticals' share price has been higher and its results have exceeded expectations, with a net profit of 2020H1 (552-620 million yuan) or more than the full year 2019 (570 million yuan).
    -meter net data show that this year Huahai Pharmaceutical sane has 6 varieties (13 standards) approved and treated the same, 1 new drug 3 indications approved clinical.
    the third batch of tape procurement is about to start, Huahai Pharmaceutical s3 "light foot" varieties ready to be launched.
    class 1 new drug attack, 6 varieties were approved into the Bureau of 4 large over 1 billion market recently, Huahai Pharmaceuticals announced that its subsidiary class 1 biological drug HB0017 injection two new indications approved clinical.
    So far, the company has received clinical trial notices for three clinical trials of indications (psoriasis, psoriasis arthritis and mandatory spinabitis) reported to the State Drug Administration for the HB0017 injection program.
    HB0017 injection is a monoclonal antibody targeted at interleukin-17 (IL-17) for the treatment of psoriasis, psoriasis arthritis and mandatory spina bifida, IL-17 is an important therapeutic target for this type of disease.
    foreign-listed same-target (IL-17/IL-17 receptor) drugs include Cosentyx (Skuchiyu sepsis), Taltz (Ichzhusmotod), and Siliq.
    no other equivalent drugs have been listed in China, except for Cosentyx and Taltz, which have been approved for sale in 2019.
    generics, six varieties (13 rules) have been approved for listing in Huahai Pharmaceuticals so far this year.
    six varieties were reported according to the newly registered classification, approved and treated as consistent evaluation.
    , alysium tablets, lamothreeium tablets for the first review, left Eablytan slow release film for the second review.
    Huahai Pharmaceuticals approved product competition pattern in 2020 Minet net data show that the four generic drugs such as O Nitrogen, Zo Eirasitan, Entikawe, Aliquine in 2019 in China's public medical institutions terminal sales of more than 1 billion yuan.
    in addition to Entikave tablets, Huahai Pharmaceuticals approved five varieties for nervous system drugs.
    in recent years, the domestic nervous system drug market has been increasing year by year.
    data show that in 2019 China's public medical institutions end-of-nervous drug sales of more than 108.3 billion yuan.
    China's public medical institutions terminal nervous system drug sales (units: 10,000 yuan) left E-Lacitan tablets, Entikawe tablets for the first batch of varieties, because only this year was approved, Huahai Pharmaceuticals missed the opportunity to collect the amount of production.
    Ao nitrogen flat-mouth edifice for the third batch of proposed collection varieties, Huahai Pharmaceutical stake is expected to quickly open the market through the collection of winning bids.
    left E-Lacitan slow release film domestic market only Xinlitai, Huahai Pharmaceutical simply approved production, Aliquin tablets, Lamo sane tablets temporarily for Huahai Pharmaceuticals exclusive review, 3 varieties are not included in the collection.
    21 over-rated varieties, 13 new products on the road Huahai pharmaceutical industry through / as if you pass the consistency evaluation of varieties in the rice network consistency evaluation database shows that at present, Huahai Pharmaceuticals has 21 varieties (37 standards) through or as if through the consistency evaluation.
    21 varieties are mainly neuropathic drugs, cardiovascular drugs and systemic anti-infective drugs, involving a total of 7 drug subcategories.
    , 6 over-rated varieties for the role of renin-angiotensin system drugs, 4 rated varieties for psycho-excitement drugs, psycho-stabilizing drugs, anti-epileptic drugs, anti-viral drugs all over the body have 3 varieties have been evaluated.
    from the evaluation order, Huahai Pharmaceutical s11 varieties of 13 for the first review.
    , 6 varieties, such as alysium tablets, lamothere tablets, Renopri tablets, Fusinpri sodium tablets, Vulcan tablets, nevira flat tablets, etc., are exclusive.
    According to MED China Drug Review Database 2.0, Huahai Pharmaceuticals has 12 varieties (25 acceptance numbers) of generic drugs under review and submits listing applications according to the new registration classification (imitation 3, 4) and will be approved for production as if they will pass the same consistency evaluation.
    five varieties were included in the priority review, namely, devastasaban tablets, timisatan tablets, timisatan hydrochloroquine tablets, omexataneste hydrochloroquine tablets, and sascatan hydrochloroquine tablets.
    from the treatment category, Huahai Pharmaceutical seisluded generic drugs mainly layout cardiovascular drugs, nervous system drugs and other fields.
    , the drug acting on the renin-angiotensin system has 6 varieties, psychostable drugs have 3 varieties, anti-epileptic drugs have 2 varieties.
    Huahai Pharmaceuticals in the review of the new registered classified generic drug half-year net profit is expected to be 552-620 million yuan! Run-off 2019 full year? Huahai Pharmaceuticals reported results (units: billion yuan) recently, Huahai Pharmaceuticals issued a 2020 half-year results advance announcement, 2020 H1 to achieve the net profit attributable to shareholders of listed companies is expected to be between 552 million yuan to 620 million yuan, an increase of about 65% to 85% year-on-year. the main reasons for the pre-increase in
    performance are: 1, the domestic preparation is mainly with the promotion of centralized procurement, the company relies on the expansion of the alliance region in the selection opportunity, product market coverage can be rapidly improved;
    note stake, Huahai Pharmaceuticals' net profit of 2020H1 (552 million yuan-620 million yuan) will exceed 2019 (570 million yuan).
    2018H1-2019Q1 affected by the "Shattan incident", the company's net profit growth declined, 2019Q2, with the harvest landing, the impact of the Yansatan desalination, the company's performance back to the growth track.
    the third-quarter report of 2019, Huahai Pharmaceuticals achieved a net profit of 512 million yuan, up 100.40 percent year-on-year, and a net profit of 570 million yuan in 2019, up 429.78 percent year-on-year.
    Huahai Pharmaceuticals is the world's leading supplier of Prie, satanic API, with the increase in global demand for satanic API and the European Union of the European Union of the european Union, the company's API business is expected to further grow.
    preparations, Huahai Pharmaceutical snares 9 varieties of selected national belt procurement.
    under the influence of medical reform policy such as medical insurance control fee and tape purchase, quality and cost control become the key to enterprise competition.
    benefit from the integration of intermediates, api, preparation of the complete industrial chain advantages, Huahai Pharmaceutical spout of multiple varieties after the winning bid market share increased, increased profits.
    the third batch of proposed collection varieties in the selection of Huahai Pharmaceuticalindustry in the
    state- and volume procurement, Huahai Pharmaceuticals has three evaluated varieties in the column, respectively, hydrochloric acid shequlin tablets, shattan tablets, Au nitrogen flat mouth collapse tablets.
    it is worth noting that The final sales of Shecurin oral often-release dosage type in 2019 in China's public medical institutions were 1.289 billion yuan, the original research manufacturer spent on Pfizer, and only Huahai Pharmaceuticals and Jingxin Pharmaceuticals were evaluated.
    the oral change agent type of Shatan in China in 2019 terminal sales of 4,964 million yuan, the original research manufacturers for Novartis, Shatan capsule evaluation enterprises have 4, shatan tablets have 2 enterprises.
    as a "light foot" enterprise, Huahai Pharmaceutical s3 varieties if the winning bid will achieve rapid release, improve the company's performance.
    source: Mi net database, company announcement note: statistics if there are omissions, welcome to point!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.